Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TPST Tempest Therapeutics Inc.

Trading 05-18 10:28:55 EDT

1.83

+0.00

0.00%

High1.89	Low1.83	Vol19.26K
Open1.83	D1 Closing1.83	Amplitude3.28%
Mkt Cap27.10M	Tradable Cap17.81M	Total Shares14.81M
T/O35.62K	T/O Rate0.20%	Tradable Shares9.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TPST","market":"US","secType":"STK","nameCN":"Tempest Therapeutics Inc.","latestPrice":1.83,"timestamp":1779114290144,"preClose":1.83,"halted":0,"volume":19256,"delay":0,"changeRate":0,"floatShares":9733600,"shares":14806997,"eps":-5.7,"marketStatus":"Trading","change":0,"latestTime":"05-18 10:28:55 EDT","open":1.83,"high":1.89,"low":1.83,"amount":35618.603068,"amplitude":0.032787,"askPrice":1.83,"askSize":258,"bidPrice":1.82,"bidSize":9000,"shortable":0,"etf":0,"ttmEps":-5.7,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1779134400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":1.83,"preHourTrading":{"tag":"盘前","latestPrice":1.85,"preClose":1.83,"latestTime":"08:39 EDT","volume":221,"amount":406.6129938,"timestamp":1779107963279,"change":0.02,"changeRate":0.010929,"amplitude":0.010929},"postHourTrading":{"tag":"盘后","latestPrice":1.88,"preClose":1.83,"latestTime":"19:43 EDT","volume":1908,"amount":3533.3829,"timestamp":1778888594199,"change":0.05,"changeRate":0.027322,"amplitude":0.027322},"volumeRatio":0.826005,"impliedVol":1.4125,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/TPST/wiki","defaultTab":"wiki","newsList":[{"id":"2635182729","title":"Tempest net loss widens 155% to $27.7 million in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635182729","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635182729?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:05","pubTimestamp":1778792748,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics posted a wider net loss of USD 27.7 million for quarter ended March 31, 2026, up 155% from a year earlier as operating loss widened to USD 27.72 million, up 153%.Acquired in-process R&D expense rose to USD 22.18 million, while general and administrative costs increased 64% to USD 5.43 million.R&D expense dropped 99% to USD 114,000 due to re-prioritizing efforts toward exploring strategic alternatives initiated in April 2025 and culminating in the February 2026 asset acquisition.Cash and cash equivalents fell to USD 1.8 million as of March 31, 2026, down from USD 7.7 million at Dec. 31, 2025, with management flagging substantial doubt about going-concern status within 12 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or lega","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL1JrtB9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635725036","title":"Tempest Therapeutics Q1 net loss widens on asset acquisition costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2635725036","media":"Reuters","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635725036?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:31","pubTimestamp":1778790717,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics Q1 net loss widens on asset acquisition costsOverviewUS CAR-T therapy developer's Q1 net loss widened due to asset acquisition costsResearch and development expenses fell sharply ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL1N41R1AX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635258317","title":"Tempest Therapeutics Q1 Operating Income USD -27.719 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635258317","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635258317?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:15","pubTimestamp":1778789701,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX149052:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635772538","title":"Press Release: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635772538","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635772538?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:15","pubTimestamp":1778789700,"startTime":"0","endTime":"0","summary":"Announced Cincinnati Children's Applied Gene and Cell Therapy Center  as Lead Manufacturing Partner. Appointed Andrew Fang, Ph.D., as Head of Business Development. BRISBANE, Calif., May 14, 2026  -- Tempest Therapeutics, Inc.  , a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update.\"We made strong progress in the first quarter as we continued to execute across our lead program TPST-2003,\" said Matt Angel, Ph.D., President and Chief Executive Officer of Tempest. \"We advanced key activities supporting the planned initiation of our U.S. registrational study of TPST-2003 in patients with rrMM, including announcing our lead manufacturing partner AGCTC and taking delivery of the TPST-2003 lentiviral vector, a critical component in the manufacturing of TPST-2003. At the same time, we strengthened our ability to unlock ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMD","BK4022","BK4139","LU0963586101.USD","CRS","IE00B66KJ199.SGD","LU2065731478.USD","IE00B19Z4B17.USD","CAR","IE0031619046.USD","BK4187","TPST","BK4006","IE00B7SZL793.SGD","BK4211","CR","BK4161","BK4230","BK4195","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633004451","title":"Tempest Therapeutics Inc  expected to post a loss of 28 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633004451","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633004451?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:24","pubTimestamp":1778246645,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics Inc  expected to post a loss of28cents a share - Earnings Preview Tempest Therapeutics Inc TPST.OQ TPST.O is expected to  show no change in quarterly revenue when it reports  resu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1H8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633118225","title":"Tempest says TPST-2003 dual-target CAR-T hits 100% complete response in Phase 1 trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2633118225","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633118225?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:10","pubTimestamp":1778065808,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics presented updated early-stage clinical data at ISCT 2026 on TPST-2003, its dual-targeting CAR-T program in relapsed or refractory multiple myeloma plus POEMS syndrome.Results showed all evaluable patients who had not previously received CAR-T therapy achieved complete remission across both ongoing Phase 1 trials.Safety findings remained supportive, with no severe cytokine release syndrome or neurotoxicity reported in REDEEM-1.Dataset expanded to 44 patients treated across three studies, strengthening evidence base for the program.Company plans FDA discussions on starting a US registrational study later in 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL18PPck:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B3QW5Z07.USD","LU2095319765.USD","TPST","LU0314104364.USD","SG9999014013.SGD","SG9999014021.USD","BK4112","IE00BGHQF748.EUR","SG9999014039.USD","IE00BKPKM429.USD","BK4588","NDAQ","IE00BN0W2V16.EUR","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4139","IE00BN0W2T93.GBP","LU2210149790.SGD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633992415","title":"Jakarta, Danantara Sign Rp17.4 Trillion Waste-to-Energy Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2633992415","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633992415?lang=en_us&edition=fundamental","pubTime":"2026-05-05 13:30","pubTimestamp":1777959043,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta - The Chief Executive Officer of BPI Danantara, Rosan Roeslani, estimated that the investment for a waste-to-energy  project with a daily capacity of 8,000 tons will reach approximately Rp17.4 trillion, assuming an exchange rate of Rp17,400 per US dollar.\"If its [capacity reaches] 8,000 [tons], the investment is approximately US$1 billion,\" Rosan said at the Coordinating Ministry for Maritime Affairs and Investment office in Jakarta on Monday, May 4, 2026.The Jakarta provincial government has signed a memorandum of understanding with Danantara for the PSEL initiative, agreeing to develop waste-to-energy infrastructure in two locations.","market":"sg","thumbnail":"https://statik.tempo.co/data/2026/04/28/id_1470917/1470917_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2026/04/28/id_1470917/1470917_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2101923/jakarta-danantara-sign-rp17-4-trillion-waste-to-energy-deal","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2101923/jakarta-danantara-sign-rp17-4-trillion-waste-to-energy-deal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631516112","title":"Tempest to present TPST-2003 clinical update at ISCT annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2631516112","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631516112?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:01","pubTimestamp":1777464069,"startTime":"0","endTime":"0","summary":"Tempest to present updated clinical data on dual-targeting CD19/BCMA CAR-T candidate TPST-2003 at ISCT Scientific Annual Meeting in Dublin, May 6-9, 2026.Oral presentation on REDEEM-1 Phase 1/2a trial scheduled for May 6, 2026 .Poster reception for REDEEM-1 set for May 7, 2026 .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL8fW9KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","BK4588","BK4139","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","TPST","SG9999014013.SGD","BK4112","IE00BN0W2W23.USD","BK4585","NDAQ","IE00BKPKM429.USD","SG9999014021.USD","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629494570","title":"Tempest Therapeutics provides update on development of TPST-2003","url":"https://stock-news.laohu8.com/highlight/detail?id=2629494570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629494570?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:30","pubTimestamp":1776861021,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics (TPST) announced that it has achieved a milestone in the development of TPST-2003, Tempest’s dual-targeting CD19/BCMA CAR-T th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-provides-update-on-development-of-tpst-2003-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-provides-update-on-development-of-tpst-2003-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CAR","BK4230","BK4022","TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629046835","title":"Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T","url":"https://stock-news.laohu8.com/highlight/detail?id=2629046835","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629046835?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:00","pubTimestamp":1776859200,"startTime":"0","endTime":"0","summary":"Delivery of TPST-2003 lentiviral vector to Cincinnati Children’s Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal developmentTech transfer on track to support","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3278911/0/en/Tempest-Announces-Key-Manufacturing-Milestone-for-TPST-2003-Dual-Targeting-CD19-BCMA-CAR-T.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","BK4022","BK4139","TPST","CAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627445581","title":"Press Release: Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts","url":"https://stock-news.laohu8.com/highlight/detail?id=2627445581","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627445581?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:00","pubTimestamp":1776168000,"startTime":"0","endTime":"0","summary":"-- Adds dedicated business development leadership to support Tempest's. -- Will lead China outreach and cross-border partnership efforts. The appointment reflects Tempest's increasing emphasis on business development as a core strategic priority, including pursuing potential partnerships for its Phase 3-ready small molecule program, amezalpat, and advancing strategic collaborations across its CAR-T portfolio.Tempest continues to prioritize strategic partnerships for amezalpat, its Phase 3-ready small molecule program for hepatocellular carcinoma . Tempest previously announced clearance to proceed with a pivotal trial of amezalpat in China, building on alignment with the U.S. Food and Drug Administration  and European Medical Agency  on amezalpat's Phase 3 study design and positioning the program for potential global development. Tempest believes that these regulatory milestones also create opportunities for regional partnerships and cross-border collaborations.\"I am excited to join Tem","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","CAR","BK4022","BK4139","BK4230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624706835","title":"Tempest Therapeutics Inc - Company Will Not Receive Proceeds From Sale of Shares by Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624706835","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624706835?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:13","pubTimestamp":1775124822,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L0H7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624657057","title":"Tempest Therapeutics Inc - Prospectus Filed for Resale of up to About 2.8 Mln Shares Including Warrants - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624657057","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624657057?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:13","pubTimestamp":1775124822,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L0H7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624957046","title":"Tempest Therapeutics files to sell 2.78M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2624957046","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624957046?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:11","pubTimestamp":1775124688,"startTime":"0","endTime":"0","summary":"06:07 EDT Tempest Therapeutics (TPST) files to sell 2.78M shares of common stock for holders Published first on TheFly – the ultimate source for re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-files-to-sell-2-78m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-files-to-sell-2-78m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TPST","BK4139","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623232294","title":"Tempest Therapeutics files to sell 8.27M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2623232294","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623232294?lang=en_us&edition=fundamental","pubTime":"2026-03-31 06:05","pubTimestamp":1774908333,"startTime":"0","endTime":"0","summary":"18:00 EDT Tempest Therapeutics (TPST) files to sell 8.27M shares of common stock for holders Published first on TheFly – the ultimate source for re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-files-to-sell-8-27m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-files-to-sell-8-27m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TPST","BK4539","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623247383","title":"Tempest Therapeutics Inc - Offers up to 8.27 Mln Shares of Common Stock for Resale by Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2623247383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623247383?lang=en_us&edition=fundamental","pubTime":"2026-03-31 05:59","pubTimestamp":1774907974,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nFWN40I1E5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623346932","title":"BRIEF-Tempest Reports Year End 2025 Financial Results And Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623346932","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623346932?lang=en_us&edition=fundamental","pubTime":"2026-03-30 22:07","pubTimestamp":1774879655,"startTime":"0","endTime":"0","summary":"BRIEF-Tempest Reports Year End 2025 Financial Results And Provides Business UpdateMarch 30 (Reuters) - Tempest Therapeutics Inc TPST.O:TEMPEST REPORTS YEAR END 2025 FINANCIAL RESULTS AND PROVIDES BUSI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA9VPHWP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623348929","title":"Tempest Therapeutics Inc - Appoints Matt Angel as CEO and President","url":"https://stock-news.laohu8.com/highlight/detail?id=2623348929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623348929?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:00","pubTimestamp":1774875604,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA9VPHWP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623134816","title":"Tempest Therapeutics Inc - Reports Net Loss of $26.3 Mln and Net Loss per Share of $6.33 for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2623134816","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623134816?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:00","pubTimestamp":1774875604,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA9VPHWP:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623034894","title":"Tempest Therapeutics Inc - Announces Positive Interim Data From Redeem-1 Phase 1/2a Trial of Tpst-2003","url":"https://stock-news.laohu8.com/highlight/detail?id=2623034894","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623034894?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:00","pubTimestamp":1774875604,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA9VPHWP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tempesttx.com","stockEarnings":[{"period":"1week","weight":-0.0804},{"period":"1month","weight":-0.1368},{"period":"3month","weight":-0.2246},{"period":"6month","weight":-0.7982},{"period":"1year","weight":-0.7185},{"period":"ytd","weight":-0.3624}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.012727},{"month":2,"riseRate":0.307692,"avgChangeRate":-0.032927},{"month":3,"riseRate":0.461538,"avgChangeRate":0.000618},{"month":4,"riseRate":0.307692,"avgChangeRate":-0.113004},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.001148},{"month":6,"riseRate":0.307692,"avgChangeRate":-0.113246},{"month":7,"riseRate":0.230769,"avgChangeRate":-0.025247},{"month":8,"riseRate":0.384615,"avgChangeRate":-0.054209},{"month":9,"riseRate":0.538462,"avgChangeRate":-0.059229},{"month":10,"riseRate":0.461538,"avgChangeRate":0.94597},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.081423},{"month":12,"riseRate":0.307692,"avgChangeRate":-0.062561}],"exchange":"NASDAQ","name":"Tempest Therapeutics Inc.","nameEN":"Tempest Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tempest Therapeutics Inc.,TPST,Tempest Therapeutics Inc.股票,Tempest Therapeutics Inc.股票老虎,Tempest Therapeutics Inc.股票老虎国际,Tempest Therapeutics Inc.行情,Tempest Therapeutics Inc.股票行情,Tempest Therapeutics Inc.股价,Tempest Therapeutics Inc.股市,Tempest Therapeutics Inc.股票价格,Tempest Therapeutics Inc.股票交易,Tempest Therapeutics Inc.股票购买,Tempest Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction